Marked as
Last updated - December 13, 2025
User Score
Trust Score
Brand Score
Zenzi Pharmaceutical Industries Private Limited, incorporated in 2005 in Murbad, Maharashtra, India, specializes in manufacturing generic medicinal products and contract services for global pharmaceutical needs.Under Managing Director Jacob Sporon-Fiedler, the firm faces a 2025 FDA Warning Letter for cGMP violations, including record refusals, leading to an ongoing U.S. import ban on all its drugs.
CEO
High Risk
Based on the available data, we advise consumers to avoid this Company altogether.
This advisory is based on an aggregate risk score derived from OSINT, Adverse Media, Reviews, and Risk Factors identified in our research.
You are likely to be at great risk by engaging in any sort of consumer-related activity with this entity.
Based on the available data, we recommend that employees exercise extreme caution or reconsider association with this Company.
This advisory stems from an aggregate risk score compiled from OSINT, Adverse Media, Reviews, and Risk Factors uncovered in our analysis.
You are likely to face significant risks by pursuing or maintaining employment with this entity.
Medium Risk
Based on the available data, we recommend investors and bankers proceed with caution regarding this Company.
This advisory is informed by a medium-risk score based on OSINT, Adverse Media, Reviews, and Risk Factors identified through our investigation.
Financial involvement with this entity may carry moderate risks to your interests.
Safe to Onboard
Enhanced Due Diligence required
Do Not Onboard
Monitor adverse media every 6 months
File SAR (Suspicious Activity Report) is warranted
Escalation to compliance committee
None
Fullname
CIN
Director1
Director2
Director3
Founded
Incorporated
Jurisdiction
ROC
Location
City
State
Country
Category
Sector
Revenue
RevenueYear
Employees
AuthorizedCapital
PaidupCapital
Village
Type
ImportAlert
No, Zenzi’s FDA violations and Sporon-Fiedler’s criminal past risk unsafe medications.
Zenzi’s record refusals led to a 2025 import ban for potential drug adulteration.
FDA’s alert flags Zenzi drugs as risky, blocking imports to prevent health hazards.
His 2019 steroid smuggling conviction links Zenzi to unregulated drug dangers.
Yes, Sporon-Fiedler’s history and Zenzi’s violations risk harmful, substandard drugs.
Zenzi’s non-compliance under Sporon-Fiedler undermines global drug safety standards.
Regulatory and Compliance Screening
Litigation and Legal Proceedings
Reputational and Adverse Media Risks
Geographic and Jurisdictional Risk
What you see here scratches the surface
We offer reward for actionable intel
150 characters maximum
First Detected
Sentiment Analysis
Reach
POV
Risk Factor
Traffic Source
SERP
Share of Voice
Primary Keyword
Other Red-Flags and Adverse News
Based on user engagement on this review profile, ProConsumer will decide to publish its Risk Audit report for public if a threshold engagement, traffic and user input is achieved.
Known Assets: [Real estate, investments, companies]
Suspicious Transactions
Liabilities: [Bankruptcies, defaults, debts]
Wealth Sources: [Legitimate / Unclear / High-risk]
Bank Relationships
Ultimate Beneficial Owner(s) (UBOs)
Shareholding structure
Associated entities & subsidiaries
Offshore / shell company links
Trusts / Nominee arrangements
Business Model Assessment
All comments are user-generated content and may not be verified. They represent the personal opinions of the public and should not be relied upon. These comments do not influence or determine our overall rating.
1.7
2
2.3
Highly experienced
Well-recognized name
Faced allegations of scamming others
Allegedly sold fake silver
Sued multiple times
Unregulated industry
Alarming number of complaints online
Δ
Engagement with Zenzi Pharmaceuticals carries elevated consumer risk, with advisories warning that the company’s products and services may pose health and safety hazards due to unresolved regulatory concerns and questionable quality assurance practices.
1/5
2/5
3/5
Due to regulatory non‑cooperation, all drug products from the Zenzi facility are subject to detention or refusal at U.S. ports, creating substantial market access risk for distributors and patients reliant on these medicines.The FDA import ban also allows authorities to withhold approval of any future applications or supplements that list the Zenzi facility as a manufacturer, restricting future business opportunities.
Zenzi Pharmaceuticals has been assigned a medium‑risk classification for financial partners and a high‑risk classification for consumers and potential employees, indicating significant adverse risk factors in its public profile.In 2025, the U.S. Food and Drug Administration (FDA issued a Warning Letter to Zenzi and placed all products manufactured by the firm on Import Alert
UProFX is an unregulated forex and CFD trading platform reportedly operated by an Estonia-based entity, offering trading in currencies, commodities, and cryptocurrencies. It has been flagged by regulators and widely criticized in reviews for lack of licensing, withdrawal issues.
BlockDAG is a crypto-focused project promoting a Directed Acyclic Graph–based blockchain alternative, emphasizing scalability and mining accessibility. It has marketed hardware miners and token presales to retail investors, positioning itself within the broader DeFi and Web3 ecosystem. Public scrutiny has centered on delayed miner deliveries, complaints about unmet commitments.
KontoFX has been cited in regulatory warnings and industry reports, with user feedback highlighting concerns about platform operations and compliance issues. Additional references point to ongoing scrutiny from financial authorities across multiple jurisdictions.
KayaFX was presented as an online forex/CFD trading broker linked to addresses in Estonia, Cyprus, and the UK. Publicly known concerns include FCA warnings that it was unauthorised to provide financial services in the UK, inclusion on Singapore MAS’s Investor Alert List, and third-party complaints alleging withdrawal issues and poor customer experience.
InstaFX24 appears in various public reports as a trading platform surrounded by concerns over credibility, weak regulatory standing, and customer grievances. Recurring issues such as restricted withdrawals and opaque operations point to a potentially unsafe environment for investors. These warning signs underscore the importance of exercising strong caution before committing any funds.
Coinbase is a U.S.-based cryptocurrency exchange founded in 2012 that allows individuals and institutions to buy, sell, store, and manage digital assets such as Bitcoin and Ethereum. Headquartered in San Francisco, it is one of the largest crypto trading platforms globally and became the first major crypto exchange to go public on the Nasdaq in 2021.
Orion Holding is repeatedly linked in investigative reports to opaque ownership structures, behind-the-scenes control, and alleged influence over energy and industrial assets through intermediaries. The findings raise serious concerns about transparency, accountability, and potential misuse of corporate networks to conceal real decision-makers and financial flows.
Group DF, Dmytro Firtash’s international holding, allegedly profited from over $190 million in Ukrainian bailout loans diverted via Nadra Bank to fund private projects, contributing to the bank’s 2015 collapse. Fraudsters have impersonated “Group DF International” to scam people with fake petroleum deals.
Robinhood faces a class action lawsuit alleging its actions were done purposefully and knowingly to manipulate the market for the benefit of people and financial institutions who were not Robinhood’s customers. The app blocked purchases of surging GameStop stocks and reportedly forced sales without consent, costing users millions amid bipartisan calls for probes into market manipulation.
© 2025 Proconsumer. All rights reserved.